Colorectal Cancer

Mutation discordance between primary and metastatic sites in colorectal cancer (CRC) may occur more often than previously understood, opening the door for potential new therapeutic approaches to treating the disease.

Advanced Colorectal Cancer with Marwan G. Fakih, MD

Advanced Colorectal Cancer with Marwan G. Fakih, MD

Mikhail Fedyanin, MD, medical oncologist, Russian Academy of Medical Sciences, Moscow, discusses some of the factors associated with discordance in mutation status in metastatic colorectal cancer during the 2016 ESMO Congress.

Advanced Colorectal Cancer with Michael Morse, MD

Advanced Colorectal Cancer with Michael Morse, MD

A genetic understanding of dMMR in rectal cancer could lead the way to precision medicine for these subgroups of patients

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses the need for better surrogate parameters for overall survival in colorectal cancer.

According to findings of a recent study, obesity is more prevalent in cancer survivors, specifically in those with a history of breast or colorectal cancer (CRC), compared with those without any history of disease.

Axel Grothey, MD, medical oncologist, Department of Oncology, Mayo Clinic, discusses the role of sidedness in tumor location in colorectal cancer.

Combined inhibition of the PD-L1/PD-1 axis with atezolizumab (Tecentriq) and the MEK pathway with cobimetinib (Cotellic) showed promising clinical activity and a good safety profile in heavily pretreated patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC), according to findings from a phase 1b study presented at the 2016 World Congress on Gastrointestinal Cancer.

MABp1 (Xilonix), a novel anti–interleukin 1-alpha (IL-1α) antibody, was safe and well tolerated, and demonstrated a significant impact on symptoms, compared with placebo, for patients with advanced colorectal cancer (CRC), according to findings from a phase III study presented at the 2016 World Congress of Gastrointestinal Cancer.

Colorectal cancer mortality rates have been on the decline in California for both men and women since the mid-1990s, but for Hispanic men, rates have remained essentially unchanged.